Chris Schott
Stock Analyst at J.P. Morgan
(4.61)
# 981
Out of 5,099 analysts
649
Total ratings
60.6%
Success rate
7.9%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPRX Royalty Pharma | Maintained: Buy | $62 → $74 | $66.40 | +11.45% | 11 | Nov 4, 2026 | |
| PFE Pfizer | Reiterated: Hold | $30 | $30.00 | - | 93 | Nov 3, 2026 | |
| GILD Gilead Sciences | Rated: Buy | $170 → $190 | $167.47 | +13.45% | 36 | Oct 30, 2026 | |
| LLY Eli Lilly and Company | Rated: Buy | $1,500 → $1,650 | $1,409.38 | +17.07% | 76 | Oct 30, 2026 | |
| MRK Merck & Co. | Rated: Buy | $165 → $175 | $144.67 | +20.96% | 38 | Oct 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterated: Buy | $950 → $1,050 | $973.36 | +7.87% | 35 | Oct 30, 2026 | |
| BIIB Biogen | Reiterated: Buy | $325 | $248.93 | +30.56% | 22 | Oct 28, 2026 | |
| AMRX Amneal Pharmaceuticals | Rated: Buy | $24 | $20.21 | +18.75% | 22 | Oct 22, 2026 | |
| PRGO Perrigo Company | Reiterated: Hold | $15 | $15.70 | -4.46% | 32 | Oct 21, 2026 | |
| VTRS Viatris | Rated: Hold | $18 → $20 | $18.92 | +5.71% | 30 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $33 | $24.57 | +34.31% | 24 | Oct 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $775 → $750 | $672.04 | +11.60% | 16 | Oct 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $115 | $82.99 | +38.57% | 17 | Oct 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ILA 15,702 | ILA 13,570 | +15.71% | 2 | Oct 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $285 → $300 | $286.00 | +4.90% | 40 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $73 | $61.71 | +18.30% | 43 | Oct 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $270 → $285 | $266.17 | +7.07% | 22 | Sep 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $300 → $350 | $461.26 | -24.12% | 12 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $12 → $11 | $13.85 | -20.58% | 13 | Feb 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $9 → $8 | $0.8056 | n/a | 9 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $11.41 | n/a | 41 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $1.78 | n/a | 3 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €85.67 → €87.46 | €149.15 | n/a | 2 | Mar 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $43 → $54 | $36.39 | n/a | 4 | Feb 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 2 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $0.173 | n/a | 3 | Nov 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $12.05 | n/a | 1 | Oct 17, 2013 |
Royalty Pharma
Nov 4, 2026
Maintained: Buy
Price Target: $62 → $74
Current: $66.40
Upside: +11.45%
Pfizer
Nov 3, 2026
Reiterated: Hold
Price Target: $30
Current: $30.00
Upside: -
Gilead Sciences
Oct 30, 2026
Rated: Buy
Price Target: $170 → $190
Current: $167.47
Upside: +13.45%
Eli Lilly and Company
Oct 30, 2026
Rated: Buy
Price Target: $1,500 → $1,650
Current: $1,409.38
Upside: +17.07%
Merck & Co.
Oct 30, 2026
Rated: Buy
Price Target: $165 → $175
Current: $144.67
Upside: +20.96%
Regeneron Pharmaceuticals
Oct 30, 2026
Reiterated: Buy
Price Target: $950 → $1,050
Current: $973.36
Upside: +7.87%
Biogen
Oct 28, 2026
Reiterated: Buy
Price Target: $325
Current: $248.93
Upside: +30.56%
Amneal Pharmaceuticals
Oct 22, 2026
Rated: Buy
Price Target: $24
Current: $20.21
Upside: +18.75%
Perrigo Company
Oct 21, 2026
Reiterated: Hold
Price Target: $15
Current: $15.70
Upside: -4.46%
Viatris
Oct 21, 2026
Rated: Hold
Price Target: $18 → $20
Current: $18.92
Upside: +5.71%
Oct 16, 2026
Reiterated: Buy
Price Target: $33
Current: $24.57
Upside: +34.31%
Oct 16, 2026
Rated: Buy
Price Target: $775 → $750
Current: $672.04
Upside: +11.60%
Oct 16, 2026
Reiterated: Buy
Price Target: $115
Current: $82.99
Upside: +38.57%
Oct 11, 2026
Reiterated: Buy
Price Target: ILA 15,702
Current: ILA 13,570
Upside: +15.71%
Oct 8, 2026
Rated: Buy
Price Target: $285 → $300
Current: $286.00
Upside: +4.90%
Oct 8, 2026
Reiterated: Buy
Price Target: $73
Current: $61.71
Upside: +18.30%
Sep 29, 2026
Reiterated: Hold
Price Target: $270 → $285
Current: $266.17
Upside: +7.07%
Aug 6, 2026
Reiterated: Hold
Price Target: $300 → $350
Current: $461.26
Upside: -24.12%
Feb 13, 2026
Reiterated: Sell
Price Target: $12 → $11
Current: $13.85
Upside: -20.58%
May 25, 2023
Reiterated: Hold
Price Target: $9 → $8
Current: $0.8056
Upside: n/a
Jul 28, 2022
Downgraded: Hold
Price Target: n/a
Current: $11.41
Upside: n/a
May 19, 2020
Downgraded: Hold
Price Target: n/a
Current: $1.78
Upside: n/a
Mar 9, 2020
Reiterated: Buy
Price Target: €85.67 → €87.46
Current: €149.15
Upside: n/a
Feb 20, 2020
Reiterated: Hold
Price Target: $43 → $54
Current: $36.39
Upside: n/a
May 13, 2019
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Nov 17, 2017
Reiterated: Buy
Price Target: $35
Current: $0.173
Upside: n/a
Oct 17, 2013
Downgraded: Hold
Price Target: n/a
Current: $12.05
Upside: n/a